# Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

> **NCT03155945** · PHASE2 · COMPLETED · sponsor: **Arena Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Crohn's Disease
- Abdominal Pain

## Interventions

- **DRUG:** Olorinab

## Key facts

- **NCT ID:** NCT03155945
- **Lead sponsor:** Arena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-19
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03155945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03155945, "Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03155945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*